Advertisement
Document › Details
Orchard Therapeutics Ltd.. (1/2/19). "Press Release: Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019". Boston & London.
Region | San Francisco, CA | |
Country | United States (USA) | |
Organisation | Orchard Therapeutics plc (Nasdaq: ORTX) | |
Group | Kyowa Kirin (Group) | |
Organisation 2 | J.P. Morgan Securities LLC | |
Group | JPMorgan Chase (Group) | |
Product | J.P. Morgan 37th Annual Healthcare Conference 2019 San Francisco | |
Product 2 | gene therapy | |
Index term | Orchard Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Orchard presents at JP Morgan Healthcare Conference 2019 | |
Person | Leck, Renee (Orchard Therapeutics 201901 Corporate + Investor Contact) | |
Person 2 | Blum, Allison (LifeSci Public Relations 201712) | |
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 3:00 p.m. PST.
A live webcast of the presentation will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. A replay of the webcast will be archived on the Orchard website following the presentation.
About Orchard
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.
Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis, the first autologous ex vivo gene therapy approved by the European Medicines Agency for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for primary immune deficiencies, neurometabolic disorders and hemoglobinopathies include three advanced registrational studies for ADA-SCID, metachromatic leukodystrophy (MLD) and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline.
Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston.
Contacts
Corporate & Investor contact
Renee Leck
Orchard Therapeutics
+1 862-242-0764
Renee.Leck@orchard-tx.com
Media contact
Allison Blum, Ph.D.
LifeSci Public Relations
+1 646-627-8383
Allison@lifescipublicrelations.com
Record changed: 2024-06-05 |
Advertisement
More documents for Kyowa Kirin (Group)
- [1] Annogen B.V.. (6/4/24). "Press Release: Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters". Amsterdam....
- [2] Orchard Therapeutics plc. (1/24/24). "Press Release: Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases". Tokyo, London & Boston, MA....
- [3] Orchard Therapeutics plc. (10/5/23). "Press Release: Kyowa Kirin to Acquire Orchard Therapeutics". Tokyo, London & Boston, MA....
- [4] Fountain Healthcare Partners. (11/2/20). "Press Release: Fountain Healthcare Partners Announces Final Close of €125 Million for Fund III"....
- [5] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
- [6] 4BIO Capital (4BIO Ventures Management Ltd.). (9/9/19). "Press Release: 4BIO Capital Raises $50 million in First Close of New Advanced Therapies Fund". London & Boston, MA....
- [7] GlaxoSmithKline plc. (8/23/19). "Press Release: GSK Announces Positive Headline Results from the Pivotal DREAMM-2 Study for Multiple MMyeloma". London....
- [8] GlaxoSmithKline plc. (8/21/19). "Press Release: GSK Submits First Regulatory Application for Daprodustat in Japan for Patients with Renal Anaemia Due to Chronic Kidney Disease". London....
- [9] Orchard Therapeutics Ltd.. (3/27/19). "Press Release: Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD". Boston, MA & London....
- [10] Orchard Therapeutics Ltd.. (3/21/19). "Press Release: Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights". Boston, MA & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top